NMNicole Martin

Nicole Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicole Martin has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Expanding the phenotypic spectrum of NOTCH1 variants: clinical manifestations in families with congenital heart disease

    by Kaitlin J. Stanley, Kelsey J. Kalbfleisch, Olivia M. Moran, Rajiv R. Chaturvedi, Maian Roifman, Xin Chen, Roozbeh Manshaei, Nicole Martin, Simina McDermott, Vanda McNiven, et al.

    Pathogenic variants in NOTCH1 are associated with non-syndromic congenital heart disease (CHD) and Adams–Oliver syndrome (AOS). The clinical presentation of individuals with damaging NOTCH1 variants is characterized by variable expressivity and incomplete penetrance; however, data on systematic phenotypic characterization are limited. We report the genotype and phenotype of a cohort of 33 individuals (20 females, 13 males; median age 23.4 years, range 2.5–68.3 years) from 11 families with causative NOTCH1 variants (9 inherited, 2 de novo; 9 novel), ascertained from a proband with CHD. We describe the cardiac and extracardiac anomalies identified in these 33 individuals, only four of whom met criteria for AOS. The most common CHD identified was tetralogy of Fallot, though various left- and right-sided lesions and septal defects were also present. Extracardiac anomalies identified include cutis aplasia (5/33), cutaneous vascular anomalies (7/33), vascular anomalies of the central nervous system (2/10), Poland anomaly (1/33), pulmonary hypertension (2/33), and structural brain anomalies (3/14). Identification of these findings in a cardiac proband cohort supports NOTCH1-associated CHD and NOTCH1-associated AOS lying on a phenotypic continuum. Our findings also support (1) Broad indications for NOTCH1 molecular testing (any familial CHD, simplex tetralogy of Fallot or hypoplastic left heart); (2) Cascade testing in all at-risk relatives; and (3) A thorough physical exam, in addition to cardiac, brain (structural and vascular), abdominal, and ophthalmologic imaging, in all gene-positive individuals. This information is important for guiding the medical management of these individuals, particularly given the high prevalence of NOTCH1 variants in the CHD population.


  • Disease management interventions for heart failure

    by Andrea Takeda, Nicole Martin, Rod S Taylor, Stephanie Jc Taylor

    Background Despite advances in treatment, the increasing and ageing population makes heart failure an important cause of morbidity and death worldwide. It is associated with high healthcare costs, partly driven by frequent hospital readmissions. Disease management interventions may help to manage people with heart failure in a more proactive, preventative way than drug therapy alone. This is the second update of a review published in 2005 and updated in 2012. Objectives To compare the effects of different disease management interventions for heart failure (which are not purely educational in focus), with usual care, in terms of death, hospital readmissions, quality of life and cost‐related outcomes. Search methods We searched CENTRAL, MEDLINE, Embase and CINAHL for this review update on 9 January 2018 and two clinical trials registries on 4 July 2018. We applied no language restrictions. Selection criteria We included randomised controlled trials (RCTs) with at least six months' follow‐up, comparing disease management interventions to usual care for adults who had been admitted to hospital at least once with a diagnosis of heart failure. There were three main types of intervention: case management; clinic‐based interventions; multidisciplinary interventions. Data collection and analysis We used standard methodological procedures expected by Cochrane. Outcomes of interest were mortality due to heart failure, mortality due to any cause, hospital readmission for heart failure, hospital readmission for any cause, adverse effects, quality of life, costs and cost‐effectiveness. Main results We found 22 new RCTs, so now include 47 RCTs (10,869 participants). Twenty‐eight were case management interventions, seven were clinic‐based models, nine were multidisciplinary interventions, and three could not be categorised as any of these. The included studies were predominantly in an older population, with most studies reporting a mean age of between 67 and 80 years. Seven RCTs were in upper‐middle‐income countries, the rest were in high‐income countries. Only two multidisciplinary‐intervention RCTs reported mortality due to heart failure. Pooled analysis gave a risk ratio (RR) of 0.46 (95% confidence interval (CI) 0.23 to 0.95), but the very low‐quality evidence means we are uncertain of the effect on mortality due to heart failure. Based on this limited evidence, the number needed to treat for an additional beneficial outcome (NNTB) is 12 (95% CI 9 to 126). Twenty‐six case management RCTs reported all‐cause mortality, with low‐quality evidence indicating that these may reduce all‐cause mortality (RR 0.78, 95% CI 0.68 to 0.90; NNTB 25, 95% CI 17 to 54). We pooled all seven clinic‐based studies, with low‐quality evidence suggesting they may make little to no difference to all‐cause mortality. Pooled analysis of eight multidisciplinary studies gave moderate‐quality evidence that these probably reduce all‐cause mortality (RR 0.67, 95% CI 0.54 to 0.83; NNTB 17, 95% CI 12 to 32). We pooled data on heart failure readmissions from 12 case management studies. Moderate‐quality evidence suggests that they probably reduce heart failure readmissions (RR 0.64, 95% CI 0.53 to 0.78; NNTB 8, 95% CI 6 to 13). We were able to pool only two clinic‐based studies, and the moderate‐quality evidence suggested that there is probably little or no difference in heart failure readmissions between clinic‐based interventions and usual care (RR 1.01, 95% CI 0.87 to 1.18). Pooled analysis of five multidisciplinary interventions gave low‐quality evidence that these may reduce the risk of heart failure readmissions (RR 0.68, 95% CI 0.50 to 0.92; NNTB 11, 95% CI 7 to 44). Meta‐analysis of 14 RCTs gave moderate‐quality evidence that case management probably slightly reduces all‐cause readmissions (RR 0.92, 95% CI 0.83 to 1.01); a decrease from 491 to 451 in 1000 people (95% CI 407 to 495). Pooling four clinic‐based RCTs gave low‐quality and somewhat heterogeneous evidence that these may result in little or no difference in all‐cause readmissions (RR 0.90, 95% CI 0.72 to 1.12). Low‐quality evidence from five RCTs indicated that multidisciplinary interventions may slightly reduce all‐cause readmissions (RR 0.85, 95% CI 0.71 to 1.01); a decrease from 450 to 383 in 1000 people (95% CI 320 to 455). Neither case management nor clinic‐based intervention RCTs reported adverse effects. Two multidisciplinary interventions reported that no adverse events occurred. GRADE assessment of moderate quality suggested that there may be little or no difference in adverse effects between multidisciplinary interventions and usual care. Quality of life was generally poorly reported, with high attrition. Low‐quality evidence means we are uncertain about the effect of case management and multidisciplinary interventions on quality of life. Four clinic‐based studies reported quality of life but we could not pool them due to differences in reporting. Low‐quality evidence indicates that clinic‐based interventions may result in little or no difference in quality of life. Four case management programmes had cost‐effectiveness analyses, and seven reported cost data. Low‐quality evidence indicates that these may reduce costs and may be cost‐effective. Two clinic‐based studies reported cost savings. Low‐quality evidence indicates that clinic‐based interventions may reduce costs slightly. Low‐quality data from one multidisciplinary intervention suggested this may be cost‐effective from a societal perspective but less so from a health‐services perspective. Authors' conclusions We found limited evidence for the effect of disease management programmes on mortality due to heart failure, with...


  • Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

    by Nicole Martin, Karthick Manoharan, James Thomas, Ceri Davies, R Thomas Lumbers

    Background Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction. There is uncertainty whether these treatments are beneficial for people with heart failure with preserved ejection fraction and a comprehensive review of the evidence is required. Objectives To assess the effects of beta‐blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and mineralocorticoid receptor antagonists in people with heart failure with preserved ejection fraction. Search methods We searched CENTRAL, MEDLINE, Embase and two clinical trial registries on 25 July 2017 to identify eligible studies. Reference lists from primary studies and review articles were checked for additional studies. There were no language or date restrictions. Selection criteria We included randomised controlled trials with a parallel group design enrolling adult participants with heart failure with preserved ejection fraction, defined by a left ventricular ejection fraction of greater than 40 percent. Data collection and analysis Two review authors independently selected studies for inclusion and extracted data. The outcomes assessed included cardiovascular mortality, heart failure hospitalisation, hyperkalaemia, all‐cause mortality and quality of life. Risk ratios (RR) and, where possible, hazard ratios (HR) were calculated for dichotomous outcomes. For continuous data, mean difference (MD) or standardised mean difference (SMD) were calculated. We contacted trialists where neccessary to obtain missing data. Main results 37 randomised controlled trials (207 reports) were included across all comparisons with a total of 18,311 participants. Ten studies (3087 participants) investigating beta‐blockers (BB) were included. A pooled analysis indicated a reduction in cardiovascular mortality (15% of participants in the intervention arm versus 19% in the control arm; RR 0.78; 95% confidence interval (CI) 0.62 to 0.99; number needed to treat to benefit (NNTB) 25; 1046 participants; 3 studies). However, the quality of evidence was low and no effect on cardiovascular mortality was observed when the analysis was limited to studies with a low risk of bias (RR 0.81; 95% CI 0.50 to 1.29; 643 participants; 1 study). There was no effect on all‐cause mortality, heart failure hospitalisation or quality of life measures, however there is uncertainty about these effects given the limited evidence available. 12 studies (4408 participants) investigating mineralocorticoid receptor antagonists (MRA) were included with the quality of evidence assessed as moderate. MRA treatment reduced heart failure hospitalisation (11% of participants in the intervention arm versus 14% in the control arm; RR 0.82; 95% CI 0.69 to 0.98; NNTB 41; 3714 participants; 3 studies; moderate‐quality evidence) however, little or no effect on all‐cause and cardiovascular mortality and quality of life measures was observed. MRA treatment was associated with a greater risk of hyperkalaemia (16% of participants in the intervention group versus 8% in the control group; RR 2.11; 95% CI 1.77 to 2.51; 4291 participants; 6 studies; high‐quality evidence). Eight studies (2061 participants) investigating angiotensin converting enzyme inhibitors (ACEI) were included with the overall quality of evidence assessed as moderate. The evidence suggested that ACEI treatment likely has little or no effect on cardiovascular mortality, all‐cause mortality, heart failure hospitalisation, or quality of life. Data for the effect of ACEI on hyperkalaemia were only available from one of the included studies. Eight studies (8755 participants) investigating angiotensin receptor blockers (ARB) were included with the overall quality of evidence assessed as high. The evidence suggested that treatment with ARB has little or no effect on cardiovascular mortality, all‐cause mortality, heart failure hospitalisation, or quality of life. ARB was associated with an increased risk of hyperkalaemia (0.9% of participants in the intervention group versus 0.5% in the control group; RR 1.88; 95% CI 1.07 to 3.33; 7148 participants; 2 studies; high‐quality evidence). We identified a single ongoing placebo‐controlled study investigating the effect of angiotensin receptor neprilysin inhibitors (ARNI) in people with heart failure with preserved ejection fraction. Authors' conclusions There is evidence that MRA treatment reduces heart failure hospitalisation in heart failure with preserverd ejection fraction, however the effects on mortality related outcomes and quality of life remain unclear. The available evidence for beta‐blockers, ACEI, ARB and ARNI is limited and it remains uncertain whether these treatments have a role in the treatment of HFpEF in the absence of an alternative indication for their use. This comprehensive review highlights a persistent gap in the evidence that is currently being addressed through several large ongoing clinical trials.


  • Cochrane corner: text messaging to improve adherence to drugs for secondary prevention of cardiovascular disease

    by Alma J Adler, Juan P Casas, Nicole Martin, Caroline Free, Pablo Perel

    Despite numerous readily available low cost and effective medications for secondary prevention of cardiovascular disease (CVD), it has been shown that a substantial proportion of cardiovascular (CV) events in people with established atherosclerotic cardiovascular disease are due to poor adherence.1 Worldwide, at least 100 million people are thought to have prevalent heart disease, resulting in at least 13 million deaths each year. The majority of these deaths occur in low and middle income countries.2 Given the complexity of the problem and the variety of settings it occurs in, finding a feasible and scalable intervention to increase adherence poses challenges. Globally, there are over 7.5 billion mobile phone subscriptions, and even in low and middle income countries, the penetrance rate is over 90%. Some mobile short messages services (SMS) have been shown to improve medication adherence for chronic conditions such as HIV.3 SMS could be a potentially cost-effective and scalable intervention and do not require that the intended audience need to search for information as it is delivered to them, as opposed to health worker-based interventions that are more expensive and complex to deliver. SMS interventions are seen to be of particular interest in low and middle income countries, where it is difficult to deliver healthcare into rural and remote communities. SMS also has the advantage of having relatively few side effects.4 Despite great enthusiasm for using SMS-based interventions to improve adherence and improve health outcomes, the evidence is limited.5 In this summary, we report the results of a recent Cochrane review.6 While other systematic reviews have addressed the question of using mobile phones for all types …


  • Polyunsaturated fat intake for prevention of cardiovascular disease

    by Asmaa Abdelhamid, Nicole Martin, Charlene Bridges, Fujian Song, Katherine Ho Deane, Lee Hooper

    This is the protocol for a review and there is no The objectives are as follows: To assess the effects of altering total polyunsaturated fat intake on cardiovascular disease, and other health outcomes, in adults.


  • RCT und (Selbst-)Auswahlbias: Die Wirksamkeit von Rehabilitation am Beispiel Mobiler geriatrischer Rehabilitation von Bewohnerinnen stationärer Pflegeeinrichtungen

    by J Behrens, M Schmidt-Ohlemann, N Martin, K Grune, H Janßen, L Köhler, R Siegert, M Warnach, Jw Kraft, F Naumann, et al.

    Hintergrund: RCTs sind erfunden, um den Auswahlbias zu bewältigen. Das beste Verfahren für die Wirkungsmessung ohne Auswahlbias eines noch nicht eingeführten Verfahrens ist eine RCT. Bei eingeführten Verfahren, auf die es einen Rechtsanspruch gibt, scheinen RCTs vielen Experten weder ethisch noch sozialrechtlich vertretbar. So gibt es in der deutschen Rehabilitations- und Therapieforschung viele Studien, die verschiedene Formen von Rehabilitation vergleichen, darunter auch RCTs. Aber es gibt kaum Studien, die eine rehabilitative Intervention mit „keiner Reha“ vergleichen. Fragestellung: Sind randomisierte kontrollierte Studien medizinischer Rehabilitation, auf die es einen Rechtsanspruch gibt, versus keine Rehabilitation möglich und wenn ja, wie aufwändig sind sie und bewältigen sie überhaupt den Auswahlbias? Methodisches Vorgehen: Verschiedene Studiendesigns werden verglichen, wobei die Mobile Geriatrische Rehabilitation pflegebedürftiger Bewohnerinnen und Bewohner stationärer Pflegeeinrichtungen „im Heim“ als Beispiel dient. Dieses Beispiel entstammt einer laufenden, vom BMG geförderten multizentrischen Studie aus fünf Bundesländern. Ergebnisse: CCTs können prospektiv die Verläufe von Personen, denen eine Indikation für Mobile Geriatrische Rehabilitation zugesprochen wurde, mit und ohne mobiler Reha vergleichen – ohne Forschereinfluss auf die Zuordnung von Rehabedürftigen zu diesen Gruppen. Es kann dann festgestellt werden, ob die eine Gruppe die Rehaziele besser erreicht als die andere, ohne die Unterschiede theoretisch unbedingt kausal interpretieren zu können wie bei einer RCT. Eine RCT wäre ethisch zwar möglich im Vergleich zweier zugelassener Verfahren, z.B. stationärer versus mobiler Reha. Aber wäre sie auch im Vergleich Mobiler Reha mit überhaupt keiner Reha bei rehabedürftigen Antragstellern, die nicht lange warten können, ethisch und sozialrechtlich möglich? Nnach der Antragstellung nicht mehr. Da Rehabilitation allerdings eine Antragsleistung ist, wäre eine RCT vertretbar, wenn rehabedürftige Personen vor der Antragstellung kontaktiert würden und zu diesem frühen Zeitpunkt einer Randomisierung zustimmten. Neben dem Aufwand eines solchen Vorgehens ist allerdings noch fraglich, ob das Ziel der Randomisierung, die Bewältigung des Auswahlbias, erreicht wird. Zwar bewältigt Randomisierung den Auswahlbias der Forscher klar. Aber der Selbstauswahl-Bias der Rehabedürftigen, die sich zur Randomisierung bereit erklären, ist damit noch nicht bewältigt. Dieser Selbstauswahl-Bias wäre nur dann zu vernachlässigen, unterschieden sich die zur Randomisierung bereiten nicht von der Grundgesamtheit aller Rehabedürftigen. Generelle RCT-Diskussion: RCT ist möglich, Bewältigung des Selbstauswahl-Bias ist allerdings immer zu prüfen. Referenzen beim Verfasser.

  • Nut consumption for the primary prevention of cardiovascular disease

    by Nicole Martin, Roberta Germanò, Louise Hartley, Alma J Adler, Karen Rees

    Nuts contain a number of nutritional attributes which may be cardioprotective. A number of epidemiological studies have shown that nut consumption may have a beneficial effect on people who have cardiovascular disease (CVD) risk factors. However, results from randomised controlled trials (RCTs) are less consistent. To determine the effectiveness of nut consumption for the primary prevention of CVD. We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Web of Science Core Collection, CINAHL, Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database (HTA) and Health Economics Evaluations Database (HEED) up to 30 July 2015. We searched trial registers and reference lists of reviews for further studies. We did not apply any language restrictions. We included RCTs of dietary advice to increase nut consumption or provision of nuts to increase consumption lasting at least three months and including healthy adults or adults at moderate and high risk of CVD. The comparison group was no intervention or minimal intervention. The outcomes of interest were CVD clinical events and CVD risk factors. Two review authors independently selected trials for inclusion, abstracted the data and assessed the risk of bias in included trials. We included five trials (435 participants randomised) and one ongoing trial. One study is awaiting classification. All trials examined the provision of nuts to increase consumption rather than dietary advice. None of the included trials reported on the primary outcomes, CVD clinical events, but trials were small and short term. All five trials reported on CVD risk factors. Four of these trials provided data in a useable format for meta-analyses, but heterogeneity precluded meta-analysis for most of the analyses. Overall trials were judged to be at unclear risk of bias.There were variable and inconsistent effects of nut consumption on CVD risk factors (lipid levels and blood pressure). Three trials monitored adverse events. One trial reported an allergic reaction to nuts and three trials reported no significant weight gain with increased nut consumption. None of the included trials reported on other secondary outcomes, occurrence of type 2 diabetes as a major risk factor for CVD, health-related quality of life and costs. Currently there is a lack of evidence for the effects of nut consumption on CVD clinical events in primary prevention and very limited evidence for the effects on CVD risk factors. No conclusions can be drawn and further high quality longer term and adequately powered trials are needed to answer the review question.


  • Mobile phone text messaging to improve adherence to cardiovascular disease secondary prevention interventions

    by Alma J Adler, Nicole Martin, Javier Mariani, Carlos D Tajer, Norma C Serrano, Juan Pablo Casas, Pablo Perel


  • Top Cited Papers

    Reduction in saturated fat intake for cardiovascular disease

    by Lee Hooper, Nicole Martin, Asmaa Abdelhamid, George Davey Smith

    Background Reducing saturated fat reduces serum cholesterol, but effects on other intermediate outcomes may be less clear. Additionally it is unclear whether the energy from saturated fats that are lost in the diet are more helpfully replaced by polyunsaturated fats, monounsaturated fats, carbohydrate or protein. This review is part of a series split from and updating an overarching review. Objectives To assess the effect of reducing saturated fat intake and replacing it with carbohydrate (CHO), polyunsaturated (PUFA) or monounsaturated fat (MUFA) and/or protein on mortality and cardiovascular morbidity, using all available randomised clinical trials. Search methods We updated our searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid) and EMBASE (Ovid) on 5 March 2014. We also checked references of included studies and reviews. Selection criteria Trials fulfilled the following criteria: 1) randomised with appropriate control group; 2) intention to reduce saturated fat intake OR intention to alter dietary fats and achieving a reduction in saturated fat; 3) not multifactorial; 4) adult humans with or without cardiovascular disease (but not acutely ill, pregnant or breastfeeding); 5) intervention at least 24 months; 6) mortality or cardiovascular morbidity data available. Data collection and analysis Two review authors working independently extracted participant numbers experiencing health outcomes in each arm, and we performed random‐effects meta‐analyses, meta‐regression, subgrouping, sensitivity analyses and funnel plots. Main results We include 15 randomised controlled trials (RCTs) (17 comparisons, ˜59,000 participants), which used a variety of interventions from providing all food to advice on how to reduce saturated fat. The included long‐term trials suggested that reducing dietary saturated fat reduced the risk of cardiovascular events by 17% (risk ratio (RR) 0.83; 95% confidence interval (CI) 0.72 to 0.96, 13 comparisons, 53,300 participants of whom 8% had a cardiovascular event, I² 65%, GRADE moderate quality of evidence), but effects on all‐cause mortality (RR 0.97; 95% CI 0.90 to 1.05; 12 trials, 55,858 participants) and cardiovascular mortality (RR 0.95; 95% CI 0.80 to 1.12, 12 trials, 53,421 participants) were less clear (both GRADE moderate quality of evidence). There was some evidence that reducing saturated fats reduced the risk of myocardial infarction (fatal and non‐fatal, RR 0.90; 95% CI 0.80 to 1.01; 11 trials, 53,167 participants), but evidence for non‐fatal myocardial infarction (RR 0.95; 95% CI 0.80 to 1.13; 9 trials, 52,834 participants) was unclear and there were no clear effects on stroke (any stroke, RR 1.00; 95% CI 0.89 to 1.12; 8 trials, 50,952 participants). These relationships did not alter with sensitivity analysis. Subgrouping suggested that the reduction in cardiovascular events was seen in studies that primarily replaced saturated fat calories with polyunsaturated fat, and no effects were seen in studies replacing saturated fat with carbohydrate or protein, but effects in studies replacing with monounsaturated fats were unclear (as we located only one small trial). Subgrouping and meta‐regression suggested that the degree of reduction in cardiovascular events was related to the degree of reduction of serum total cholesterol, and there were suggestions of greater protection with greater saturated fat reduction or greater increase in polyunsaturated and monounsaturated fats. There was no evidence of harmful effects of reducing saturated fat intakes on cancer mortality, cancer diagnoses or blood pressure, while there was some evidence of improvements in weight and BMI. Authors' conclusions The findings of this updated review are suggestive of a small but potentially important reduction in cardiovascular risk on reduction of saturated fat intake. Replacing the energy from saturated fat with polyunsaturated fat appears to be a useful strategy, and replacement with carbohydrate appears less useful, but effects of replacement with monounsaturated fat were unclear due to inclusion of only one small trial. This effect did not appear to alter by study duration, sex or baseline level of cardiovascular risk. Lifestyle advice to all those at risk of cardiovascular disease and to lower risk population groups should continue to include permanent reduction of dietary saturated fat and partial replacement by unsaturated fats. The ideal type of unsaturated fat is unclear.


  • Open Access

    Reduced dietary salt for the prevention of cardiovascular disease

    by Alma J Adler, Fiona Taylor, Nicole Martin, Sheldon Gottlieb, Rod S Taylor, Shah Ebrahim

    This is an update of a Cochrane review that was first published in 2011 of the effects of reducing dietary salt intake, through advice to reduce salt intake or low-sodium salt substitution, on mortality and cardiovascular events. 1. To assess the long-term effects of advice and salt substitution, aimed at reducing dietary salt, on mortality and cardiovascular morbidity. 2. To investigate whether a reduction in blood pressure is an explanatory factor in the effect of such dietary interventions on mortality and cardiovascular outcomes. We updated the searches of CENTRAL (2013, Issue 4), MEDLINE (OVID, 1946 to April week 3 2013), EMBASE (OVID, 1947 to 30 April 2013) and CINAHL (EBSCO, inception to 1 April 2013) and last ran these on 1 May 2013. We also checked the references of included studies and reviews. We applied no language restrictions. Trials fulfilled the following criteria: (1) randomised, with follow-up of at least six months, (2) the intervention was reduced dietary salt (through advice to reduce salt intake or low-sodium salt substitution), (3) participants were adults and (4) mortality or cardiovascular morbidity data were available. Two review authors independently assessed whether studies met these criteria. A single author extracted data and assessed study validity, and a second author checked this. We contacted trial authors where possible to obtain missing information. We extracted events and calculated risk ratios (RRs) and 95% confidence intervals (CIs). Eight studies met the inclusion criteria: three in normotensives (n = 3518) and five in hypertensives or mixed populations of normo- and hypertensives (n = 3766). End of trial follow-up ranged from six to 36 months and the longest observational follow-up (after trial end) was 12.7 years. The risk ratios (RR) for all-cause mortality in normotensives were imprecise and showed no evidence of reduction (end of trial RR 0.67, 95% confidence interval (CI) 0.40 to 1.12, 60 deaths; longest follow-up RR 0.90, 95% CI 0.58 to 1.40, 79 deaths n=3518) or in hypertensives (end of trial RR 1.00, 95% CI 0.86 to 1.15, 565 deaths; longest follow-up RR 0.99, 95% CI 0.87 to 1.14, 674 deaths n=3085). There was weak evidence of benefit for cardiovascular mortality (hypertensives: end of trial RR 0.67, 95% CI 0.45 to 1.01, 106 events n=2656) and for cardiovascular events (hypertensives: end of trial RR 0.76, 95% CI 0.57 to 1.01, 194 events, four studies, n = 3397; normotensives: at longest follow-up RR 0.84, 95% CI 0.64 to 1.10, 200 events; hypertensives: RR 0.77, 95% CI 0.58 to 1.02, 192 events; pooled analysis of six trials (RR 0.81, 95% CI 0.66 to 0.98; n = 5762). These findings were driven by one trial among retirement home residents that reduced salt intake in the kitchens of the homes, thereby not requiring individual behaviour change. Advice to reduce salt showed small reductions in systolic blood pressure (mean difference (MD) -1.15 mmHg, 95% CI -2.32 to 0.02 n=2079) and diastolic blood pressure (MD -0.80 mmHg, 95% CI -1.37 to -0.23 n=2079) in normotensives and greater reductions in systolic blood pressure in hypertensives (MD -4.14 mmHg, 95% CI -5.84 to -2.43 n=675), but no difference in diastolic blood pressure (MD -3.74 mmHg, 95% CI -8.41 to 0.93 n=675). Overall many of the trials failed to report sufficient detail to assess their potential risk of bias. Health-related quality of life was assessed in one trial in normotensives, which reported significant improvements in well-being but no data were presented. Despite collating more event data than previous systematic reviews of randomised controlled trials, there is insufficient power to confirm clinically important effects of dietary advice and salt substitution on cardiovascular mortality in normotensive or hypertensive populations. Our estimates of the clinical benefits from advice to reduce dietary salt are imprecise, but are larger than would be predicted from the small blood pressure reductions achieved. Further well-powered studies would be needed to obtain more precise estimates. Our findings do not support individual dietary advice as a means of restricting salt intake. It is possible that alternative strategies that do not require individual behaviour change may be effective and merit further trials.